A comparison of mydriatic eyedrops in low-weight infants

Area of Science:

• Ophthalmology
• Neonatal Medicine
• Pharmacology

Background:

• Pupil dilation is essential for examining neonates' retinas for conditions like retinopathy of prematurity.
• Low-weight infants (<1600g) are at risk of systemic hypertension with certain phenylephrine concentrations.

Purpose of the Study:

• To identify the safest and most effective commercially available mydriatic agent for pupil dilation in low-weight neonates.
• To compare the efficacy and safety of different ophthalmic drop combinations.

Main Methods:

• Thirty low-weight infants were randomized into three groups.
• Tested agents included cyclopentolate 0.5% alone, cyclopentolate 0.5% + mydriacyl 0.5%, and phenylephrine 1% + cyclopentolate 0.2%.
• Evaluated effects on systolic blood pressure, pulse rate, pupil size, and duration of dilation.

Main Results:

• No significant changes in systolic blood pressure or pulse rate were observed with any tested drops.
• The phenylephrine 1% and cyclopentolate 0.2% combination achieved a statistically greater mean pupil dilation (2.8 mm) (P < 0.01).
• This combination also demonstrated a significantly longer duration of maximal dilation (P < 0.05).

Conclusions:

• A combination of phenylephrine 1% and cyclopentolate 0.2% is a safe and effective mydriatic agent for low-weight neonates.
• This combination offers superior pupil dilation efficacy and duration for neonatal retinal examinations.
• The study supports the use of this specific combination for improved diagnostic capabilities in vulnerable infants.